Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands

Abstract For patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), chemotherapy can prolong life and alleviate symptoms. However, expected gains may be small, not necessarily outweighing considerable toxicity and high costs. Treatment choice is to a large extent dependent on preferences of doctors and patients and data on these choices are scarce. The purpose of this study is to obtain real-world information on palliative systemic treatment and costs of R/M SCCHN in the Netherlands. In six Dutch head and neck treatment centers, data were collected... Mehr ...

Verfasser: van der Linden, Naomi
Buter, Jan
Pescott, Chris P.
Lalisang, Roy I.
de Boer, Jan Paul
de Graeff, Alexander
van Herpen, Carla M. L.
de Jong, Robert J. Baatenburg
Uyl-de Groot, Carin A.
Dokumenttyp: Artikel
Erscheinungsdatum: 2016
Reihe/Periodikum: van der Linden , N , Buter , J , Pescott , C P , Lalisang , R I , de Boer , J P , de Graeff , A , van Herpen , C M L , de Jong , R J B & Uyl-de Groot , C A 2016 , ' Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands ' , European Archives of Oto-Rhino-Laryngology , vol. 273 , no. 2 , pp. 455-464 . https://doi.org/10.1007/s00405-015-3495-y
Schlagwörter: Carcinoma / squamous cell of head and neck / Drug therapy / Costs and cost analysis
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26821776
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://cris.maastrichtuniversity.nl/en/publications/9491c78c-afa3-48fc-bd51-eaee698981a3